Abattis Signs LOI with Canadian Artesian Ice, Bottlers of Clearly Canadian Products, to Manufacture CBD-infused Mineral Water


Ryan Allway

March 13th, 2018

News, Top News


VANCOUVER, British ColumbiaMarch 13, 2018 /PRNewswire/ —

Abattis Bioceuticals Corp. (the “Company” or “Abattis “) (CSE: ATT) (OTC: ATTBF) is pleased to announce it has entered into a non-binding letter of intent (the “LOI“) with Canadian Artesian Ice Ltd. (“Canadian Artesian“) to provide Canadian Artesian with, among other things, THC- and pesticide-free cannabidiol (“CBD“) isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services and access to Abattis’s distribution and marketing channels to support the development, scalability and commercialization of a CBD-infused water for Canadian Artesian. Canadian Artesian is a bottler of Premium artesian 7.8 pH mineral water, based in Nelson, British Columbia, and is the bottler of Clearly CanadianArtesian mineral water. Pursuant to the LOI, Abattis and Canadian Artesian have agreed to negotiate in good faith the terms of a definitive research services agreement respecting the terms of their partnership.

“We are very excited about our new partnership with Canadian Artesian.” stated Rob Abenante, President and CEO of Abattis. “The bottled water market is expected to be approximately $280 billion by 2020* and we believe point of origin will be the key differentiator among big players. In light of recent research indicating that more than 60% of North American bottled water comes from municipal water sources, Canadian Artesian’s access to premium mineral well water positions it to produce a world-class line of CBD-infused mineral waters.”

“Through our partnership with Canadian Artesian, we continue to fully integrate our complete suite of downstream solutions for the cannabis and hemp markets. Navigating current and future regulatory and compliance frameworks, from analytical testing to compliance with Health Canada regulations, is becoming increasingly complex. As with our other partners, we are offering Canadian Artesian a one-stop solution to support their expansion plans into CBD-infused finished products”, added Mr. Abenante.

“We source our Premium artesian 7.8 pH mineral water from a 600-foot deep reservoir in Nelson, British Columbia. According to tests performed by the University of British Columbia, our mineral water has a similar chemical profile to mineral water from Fiji. We believe our partnership with Abattis will allow us to create a whole new category of premium functional mineral water”, stated F. Boekel, Director of Canadian Artesian.

“The market for bottled mineral water is expected to maintain solid growth over the next five years. The combination of Canadian Artesian’s premium point-of-origin water and our pesticide-, THC-free high purity CBD could set a new standard for premium pure and flavoured CBD-infused mineral waters,” added Dr. David Galvez, Senior Science Advisor at Abattis.

About Abattis Bioceuticals Corp. 

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: http://www.abattis.com

* Source: Zion Market Research.

ON BEHALF OF THE BOARD OF

ABATTIS BIOCEUTICALS CORP.,

Rob Abenante

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: http://www.abattis.com

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, intends, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: Abattis plans to provide THC- and pesticide-free CBD isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services and access to its distribution and marketing channels to support the development, scalability and commercialization of a CBD-infused water for Canadian Artesian; the negotiation of a potential definitive research services agreement with Canadian Artesian; Canadian Artesians access to premium mineral well water positioning it to produce a world-class line of CBD-infused mineral waters; the expected benefits to both Abattis and Canadian Artesian of the partiespartnership; that the partnership with Abattis will allow them to create a whole new category of premium functional mineral water; the expected growth of the market for bottled mineral water; and the combination of premium point-of-origin water and Abattiss pesticide-, THC-free high purity CBD potentially setting a new standard for premium pure and flavoured CBD-infused mineral waters. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that Abattis will not provide THC- and pesticide-free CBD isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services or access to its distribution and marketing channels to support the development, scalability and commercialization of a CBD-infused water for Canadian Artesian; that a definitive research services agreement with Canadian Artesian will not be successfully negotiated or executed; that Canadian Artesians access to premium mineral well water will not position it to produce a world-class line of CBD-infused mineral waters; that the partnership between Abattis and Canadian Artesian will not benefit either party as expected or at all; that Canadian Artesians partnership with Abattis will allow them to create a whole new category of premium functional mineral water; that the market for bottled mineral water will not grow as expected or at all; that the combination of premium point-of-origin water and Abattiss pesticide-, THC-free high purity CBD will not set a new standard for premium pure and flavoured CBD-infused mineral waters; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Companys competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Companys control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on http://www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For inquiries, please contact the Company at +1(604)674-8232 or at news@abattis.com .

 

SOURCE Abattis Bioceuticals Corp.

 

Source: PR Newswire (March 13, 2018 – 6:15 AM EDT)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading